Score Overview
Explore the 2021 public Archive ranking →
Where Eagle Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. EGRX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 1.00 | — |
1 Year2025-10-23 | $ 1.00 | 0.00% |
5 Years2021-10-22 | $ 52.29 | -98.09% |
10 Years2016-10-21 | $ 64.98 | -98.46% |
All Time2014-02-12 | $ 12.83 | -92.21% |
| Period | Last Price2026-10-22 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2014-02-12 |
|---|---|---|---|---|---|
| Price | $ 1.00 | $ 1.00 | $ 52.29 | $ 64.98 | $ 12.83 |
| Return | — | 0.00% | -98.09% | -98.46% | -92.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 257M | $ 15M | $ 15M |
| 2022 | $ 316M | $ 35M | $ 55M |
| 2021 | $ 171M | -$ 8M | $ 97M |
| 2020 | $ 187M | $ 11M | $ 103M |
| 2019 | $ 195M | $ 14M | $ 109M |
| 2018 | $ 213M | $ 31M | $ 78M |
| 2017 | $ 236M | $ 51M | $ 114M |
| 2016 | $ 189M | $ 81M | $ 52M |
| 2015 | $ 66M | $ 2M | $ 79M |
| IPO2014 | $ 19M | -$ 17M | $ 42M |
Eagle Pharmaceuticals Inc fundamental performance
Between 2017 and 2022, revenue grew from $ 236M to $ 316M and net income declined from $ 51M to $ 35M. Revenue increased in 1 of those 5 years; net income in 1.
Across Eagle Pharmaceuticals Inc's full reported history, from 2014 to 2022, revenue grew from $ 19M to $ 316M and net income went from -$ 17M to $ 35M. Revenue increased in 44% of the years measured; net income in 33%.
Eagle Pharmaceuticals Inc currently holds a 5-year HDB Score of 2.7 out of 10. How the HDB Score is calculated.
Membership
Explore EGRX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
